Establishment Labs Director Trims Position Amid Strong Revenue Growth

Establishment Labs (NASDAQ: ESTA) director Juan Jose Chacon Quiros executed an indirect sale of 37,500 shares on April 14, 2026. The transaction, conducted through Sariel Group Ltd, was valued at approximately $2.45 million based on a reported share price of $65.23. The sale was carried out under a pre-arranged 10b5-1 trading plan, suggesting strategic portfolio management rather than a reaction to non-public information. Despite the divestment, Quiros maintains a substantial stake in the medical device firm, holding a total of 1,227,697 shares across direct and indirect accounts. This activity follows a period of robust financial performance for the company. Establishment Labs reported fourth-quarter revenue of $64.6 million, a 45% increase year-over-year, while full-year revenue reached $211.1 million, representing a 27% growth rate. The company is demonstrating improved operating leverage, posting a positive adjusted EBITDA of $5.5 million for the quarter, a significant recovery from the $13.1 million loss recorded in the prior year. Management remains optimistic, projecting revenue growth to exceed 25% throughout 2026. While the stock has surged approximately 128% over the past year, the scale of this sale relative to the director's total holdings and the underlying fundamental strength suggest the move is a routine profit-taking event rather than a signal of declining confidence in the company's aesthetic and reconstructive surgery business.